Overview
Single-modality biomarkers such as tumor mutational burden (TMB) often fail to reliably predict response to immune checkpoint blockade (ICB), likely due to incomplete characterization of the complex tumor-immune interactions that influence treatment efficacy. We previously developed the composite biomarker, neoantigen presentation score (NEOPS™), which integrates neoantigen processing and presentation. NEOPS demonstrated increased performance over TMB and other single-modality biomarkers in predicting ICB response in melanoma [1,2]. Here, we combine NEOPS with the assessment of tumor immune infiltration and demonstrate more accurate patient stratification for ICB response.
